Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen s Revenues Soar, Earnings Decline in Q1

NEW YORK, April 22 (GenomeWeb News) - Invitrogen reported a decrease in earnings for the first quarter, despite a surge in revenues.

 

Revenues climbed almost 40 percent, to $251.3 million, compared to $180.6 million during the same quarter last year. Most of this increase resulted from BioDiscovery products, in particular from products Invitrogen obtained through its acquisitions of Molecular Probes and Pan Vera.

 

Research and development costs were $15.7 million, up from $10.6 million during the same quarter in 2003.

 

Net income for the quarter was $10.5 million, or $.2 per share, down from $16.9 million, or $.34 per share, during the year-ago period. Invitrogen attributed this decrease in earnings to higher amortization of intangibles from acquired businesses and to a $6.8 million charge for the retirement of high cost debt.

 

As of March 31, Invitrogen had cash and investments of $891.3 million.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.